drugset / Trial / NCT06175806

Granisetron Versus Ondansetron for Nausea and Vomiting in Pediatric Age Group

NCT06175806

Completed 160 enrolled Ain Shams University
RandomizedParallel-groupOpen-labelTreatment

Summary

The current clinical trial will include 160 children who will be presented with vomiting to the Outpatient Department of the Children's Hospital, Faculty of Medicine, Ain Shams University. Participants will be assigned randomly to receive either a dispersible film Ondansetron or oral Granisetron. After initial assessment, both groups will be followed up after 6 and 48 hours to check the frequency of vomiting, diarrhea, fever, headache as well as the return of appetite and the need for further treatment. The impact of nausea and vomiting on patients' daily lives will be assessed using a modified version of the Functional Living Index-Emesis (FLIE).

Timeline

Start
2023-09-10
Primary completion
2023-11-11
Completion
2023-11-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Granisetron Other / unclassified 40 ug/kg Oral
Subject Ondansetron Other / unclassified 4 mg Oral
Subject Ondansetron Other / unclassified 8 mg Oral

Indications

No indication recorded.